GHRP-6

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

GHRP-6 — GHS-R1a / CD36 Dual Receptor Agonist / Foundational Growth Hormone Secretagogue

GHRP-6 (Growth Hormone-Releasing Peptide-6), with the amino acid sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, is the original synthetic growth hormone secretagogue — the first in the GHRP family to specifically elicit dose-related GH release both in vitro and in vivo. Developed from structural analogs of Met-enkephalin by endocrinologist Cyril Bowers, GHRP-6 laid the pharmacological groundwork that ultimately led to the discovery of the ghrelin receptor (GHS-R1a) and ghrelin itself. Decades of research have since revealed that GHRP-6 operates through not one but two distinct receptor pathways, with cytoprotective and cardioprotective properties that function entirely independently of its GH-releasing activity. This dual-receptor profile and its long research history make GHRP-6 one of the most comprehensively characterized compounds in the secretagogue class.

Why GHRP-6’s Mechanism Is Distinctive

GHRP-6 and GHRP-2 share the same primary receptor target, but their downstream signaling diverges in a mechanistically meaningful way. GHRP-2 triggers GH release via cAMP elevation — a pathway similar to GHRH itself. GHRP-6, by contrast, drives GH secretion through intracellular calcium mobilization without raising cAMP, operating through the Gq/11-mediated phospholipase C (PLC) pathway instead. This difference in second-messenger signaling makes GHRP-6 a distinct and complementary tool in receptor pharmacology research, rather than simply an older version of GHRP-2.

The CD36 receptor pathway is GHRP-6’s most clinically interesting distinguishing feature. Preclinical research has demonstrated that GHRP-6 reduces myocardial necrosis following ischemia/reperfusion, attenuates oxidative stress, preserves mitochondrial function, and exerts anti-fibrotic effects in liver, kidney, and lung tissue — none of which are replicated by GHRH, confirming these effects are GH-independent.

Research Applications

GHRP-6 is used in studies examining:

• Pulsatile GH secretion via Ca²⁺/PLC pathway — mechanistically distinct from cAMP-dependent secretagogues
• Comparative GHRP pharmacology (GHRP-6 vs. GHRP-2 vs. ipamorelin receptor selectivity and signaling)
• GHS-R1a and CD36 dual-receptor biology and cytoprotective signaling cascades
• Cardioprotection, ischemia/reperfusion injury, and myocardial preservation models
• Multi-organ cytoprotection — hepatic, renal, pulmonary, and gastrointestinal epithelial tissue models
• Anti-fibrotic mechanisms and TGF-β-related fibrogenic cytokine modulation
• Orexigenic pathway research — the most potent ghrelin-mimetic appetite signal among synthetic GHRPs
• Sarcopenia, muscle catabolism, and anabolic/catabolic balance via GH/IGF-1 axis
• Wound healing, scar prevention, and hypertrophic scar models
• Sleep architecture and slow-wave sleep dynamics via GH pulse timing

Specifications

Reconstitution

GHRP-6 arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example (5mg vial): 5mg + 3mL BAC water = ~1.67mg/mL solution Example (10mg vial): 10mg + 3mL BAC water = ~3.33mg/mL solution

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days. Do not freeze reconstituted solution. As with all GHRPs, administration on an empty stomach is standard — elevated plasma glucose and free fatty acids blunt GH response to secretagogue stimulation.

Protocol Notes

GHRP-6 is active at microgram doses and is typically administered 1–3 times daily timed to fasted states. Its pronounced appetite stimulation onset (15–30 minutes post-injection) is predictable and receptor-mediated — this is a defining characteristic of GHRP-6 protocols and should be factored into research design.

Typical research dosing framework:

• Starting dose: 100mcg per administration
• Escalation: 100mcg is generally considered near-saturation for GH pulse per bolus; doses above 300mcg per injection show diminishing GH returns
• Frequency: 1–3x daily (subcutaneous), administered fasted; bedtime, morning, and pre-activity windows are standard in multi-injection protocols
• Study duration: 8–16 weeks; 4–8 week washout recommended between cycles to preserve receptor sensitivity
• Note: When combined with a GHRH analog (e.g., CJC-1295, sermorelin), GHRP-6 produces synergistic GH output 2–3x greater than either alone; lower GHRP-6 doses are appropriate in stacked protocols

Commonly observed effects in research models:

• Appetite / GI: Intense, rapid-onset hunger within 15–30 minutes of injection — the hallmark effect of GHRP-6 and more pronounced than any other GHRP; increased gastric motility; this effect is consistent and receptor-mediated, not dose-dependent at typical research ranges
• Endocrine: Transient ACTH and cortisol elevation; water retention common in early protocol weeks; mild insulin sensitivity reduction; transient dizziness or flushing from rapid GH spike
• Other: Somnolence post-injection (supports bedtime dosing strategy); injection site redness or mild swelling; arthralgias and peripheral numbness/tingling with prolonged use — incidence lower than with direct exogenous GH due to endogenous synthesis limits

Research Stacks

GHRP-6 is commonly paired in research settings with:

• GHRP-2 — GHRP-2 and GHRP-6 share the GHSR-1a target but differ in potency, receptor binding kinetics, and secondary effects on appetite and cortisol; co-administration studies use them to establish receptor saturation thresholds and comparative GH release curves.
• CJC-1295 No DAC / Ipamorelin — The combined GHRH and selective ghrelin receptor stimulation in this blend is studied alongside GHRP-6 to examine how stacking a less-selective GHSR agonist modifies pulse amplitude and cortisol co-secretion relative to Ipamorelin alone.
• Sermorelin — Sermorelin provides direct GHRH receptor stimulation; pairing it with GHRP-6 in research allows characterization of GH pulse architecture when GHRH and ghrelin pathways are engaged simultaneously with compounds of known pharmacokinetic profiles.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.